No studies have compared clinical outcomes after discontinuation of clozapine between patients who responded to clozapine and those who did not. Therefore, we examined 1-year clinical outcomes after clozapine discontinuation in responders and nonresponders. We reviewed data on patients who discontinued clozapine and retrospectively followed them for 1 year. Clinical information was collected from medical records starting at the initiation of clozapine administration, at discontinuation and at 1 year after discontinuation. In addition, clinical status was assessed using the Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) scales. We classified the patients into clozapine responder and nonresponder groups according to the CGI-I score. Thirty-nine patients were enrolled in this study. Olanzapine was the most common antipsychotic prescribed after clozapine discontinuation in both the responder and nonresponder groups. The mean CGI-S score significantly increased 1 year after clozapine discontinuation in the responder group and significantly decreased in the nonresponder group; there was a significant difference in changes in the CGI-S scores between the groups. The difference remained significant after controlling for clozapine dose and duration of treatment. The findings suggest that clinicians may consider continuing and discontinuing clozapine treatment for patients who responded to clozapine and those who did not, respectively.

中文翻译：

---

有反应者与无反应者在氯氮平停药后的临床结果：回顾性图表审查。

没有研究比较对氯氮平有反应的患者和没有反应的患者停用氯氮平后的临床结果。因此，我们检查了有反应者和无反应者停用氯氮平后 1 年的临床结果。我们回顾了停用氯氮平并回顾性随访 1 年的患者的数据。从开始服用氯氮平、停药时和停药后 1 年的医疗记录中收集临床信息。此外，使用临床总体印象 - 严重性 (CGI-S) 和临床总体印象 - 改善 (CGI-I) 量表评估临床状态。我们根据 CGI-I 评分将患者分为氯氮平反应组和非反应组。三十九名患者参加了这项研究。在反应组和无反应组中，奥氮平是氯氮平停药后最常见的抗精神病药。氯氮平停药 1 年后，反应组的平均 CGI-S 评分显着增加，而无反应组的平均 CGI-S 评分显着降低；各组之间的 CGI-S 评分变化存在显着差异。在控制氯氮平剂量和治疗持续时间后，差异仍然显着。研究结果表明，对于氯氮平有反应的患者和没有反应的患者，临床医生可能会考虑继续和停止氯氮平治疗。氯氮平停药 1 年后，反应组的平均 CGI-S 评分显着增加，而无反应组的平均 CGI-S 评分显着降低；各组之间的 CGI-S 评分变化存在显着差异。在控制氯氮平剂量和治疗持续时间后，差异仍然显着。研究结果表明，对于氯氮平有反应的患者和没有反应的患者，临床医生可能会考虑继续和停止氯氮平治疗。氯氮平停药 1 年后，反应组的平均 CGI-S 评分显着增加，而无反应组的平均 CGI-S 评分显着降低；各组之间的 CGI-S 评分变化存在显着差异。在控制氯氮平剂量和治疗持续时间后，差异仍然显着。研究结果表明，对于氯氮平有反应的患者和没有反应的患者，临床医生可能会考虑继续和停止氯氮平治疗。